Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
25.7M
-
Number of holders
-
97
-
Total shares
-
20.6M
-
Shares change
-
+7.53M
-
Total reported value, excl. options
-
$470M
-
Value change
-
+$169M
-
Put/Call ratio
-
0.3
-
Number of buys
-
74
-
Number of sells
-
-19
-
Price
-
$22.90
Significant Holders of Tourmaline Bio, Inc. - Common Stock, $0.0001 par value per share (TRML) as of Q1 2024
102 filings reported holding TRML - Tourmaline Bio, Inc. - Common Stock, $0.0001 par value per share as of Q1 2024.
Tourmaline Bio, Inc. - Common Stock, $0.0001 par value per share (TRML) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.6M shares
of 25.7M outstanding shares and own 80% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (2.22M shares), Deep Track Capital, LP (1.6M shares), TCG Crossover Management, LLC (1.48M shares), Blue Owl Capital Holdings LP (1.45M shares), Cormorant Asset Management, LP (1.25M shares), JENNISON ASSOCIATES LLC (1.12M shares), QVT Financial LP (948K shares), VANGUARD GROUP INC (915K shares), BRAIDWELL LP (907K shares), and Qiming U.S. Ventures Management, LLC (742K shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.